CliffBio
biologic

Ixinity

Coagulation Factor IX (Recombinant)

Loss of exclusivityApril 2027projected — 12-year biologic exclusivity estimate
CompanyMedexus Pharma →View the full company profile on CliffBio

Drug detail

Brand nameIxinity
Active ingredientCoagulation Factor IX (Recombinant)
Strength1500IU
Dosage formFor Injection
RouteIntravenous
ModalityBiologic
FDA approvalApril 2015
Marketing statusRx

More from Medexus Pharma

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Ixinity patent cliff — loss of exclusivity April 2027 | CliffBio